The Analyst Landscape: 7 Takes On GoodRx Holdings
Portfolio Pulse from Benzinga Insights
Over the past three months, 7 analysts have evaluated GoodRx Holdings (NASDAQ:GDRX), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased by 12% to $10.64. Recent analyst actions include several upgrades and new ratings, reflecting positive sentiment towards the company.
June 10, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GoodRx Holdings has received a mix of bullish and somewhat bullish ratings from analysts over the past three months. The average 12-month price target has increased by 12% to $10.64, indicating positive sentiment. Recent upgrades from firms like Morgan Stanley, RBC Capital, and Barclays suggest growing confidence in the company's performance.
The increase in the average price target and multiple upgrades from reputable firms indicate a positive short-term outlook for GoodRx Holdings. Analysts' actions reflect growing confidence in the company's performance and potential for future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100